De Jaeghere, E <br/><br/>
Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.  [electronic resource] 

 -  Acta clinica Belgica  Feb 2017 
 - 6-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>2295-3337 
<br/><br/><label>Standard No.: </label>10.1080/17843286.2016.1188455  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cystadenocarcinoma--drug therapy<br/>Female<br/>Genes, BRCA1<br/>Genes, BRCA2<br/>Genetic Testing<br/>Humans<br/>Ovarian Neoplasms--drug therapy<br/>Phthalazines--therapeutic use<br/>Piperazines--therapeutic use<br/>Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use